Pediatric Autoimmune CNS Disorders Evaluation

Expires: May 27, 2022

Presentation

View the Archived Webinar


Video length: 1 hour 8 minutes

Overview

CNS autoimmunity is increasingly recognized in children. This “Specialty Testing” webinar will address the clinical presentations, evaluation (including diagnostic antibody testing), and treatment of autoimmune pediatric CNS disorders, including encephalitides and myelopathies.

Presenter

Andrew McKeon, M.D., M.B., B.Ch.
Professor of Laboratory Medicine and Pathology and Neurology
Mayo Clinic, Rochester, Minnesota

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize key clinical features of pediatric CNS autoimmune disorders.
  • Identify appropriate diagnostic modalities.
  • Interpret diagnostic antibody test results in children.
  • Identify appropriate treatments.

Intended Audience

This webinar is designed for any provider who sees patients with neurologic diseases (e.g., neurologists, psychiatrists, and primary care physicians, including internists and family care practitioners) as well as pathologists, laboratory directors, and laboratory send-out coordinators.

Credit

The following types of credit are offered for this event:
ASCLS P.A.C.E.®

Level of instruction for this program is advanced.

To obtain credit:

  1. Watch the video.
  2. Complete the posttest and evaluation that launches immediately following the video.
  3. Generate and print your certificate(s).

ASCLS P.A.C.E.®

Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.

Faculty Disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

Additional Resources

Questions?

Contact us: mcleducation@mayo.edu

MCL Education

MCL Education

This post was developed by our Education and Technical Publications Team.